Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European value-based healthcare benchmarking: moving from theory to practice.
García-Lorenzo B, Gorostiza A, Alayo I, Castelo Zas S, Cobos Baena P, Gallego Camiña I, Izaguirre Narbaiza B, Mallabiabarrena G, Ustarroz-Aguirre I, Rigabert A, Balzi W, Maltoni R, Massa I, Álvarez López I, Arévalo Lobera S, Esteban M, Fernández Calleja M, Gómez Mediavilla J, Fernández M, Del Oro Hitar M, Ortega Torres MDC, Sanz Ferrandez MC, Manso Sánchez L, Serrano Balazote P, Varela Rodríguez C, Campone M, Le Lann S, Vercauter P, Tournoy K, Borges M, Oliveira AS, Soares M, Fullaondo A; VOICE Study Group. García-Lorenzo B, et al. Among authors: maltoni r. Eur J Public Health. 2024 Feb 5;34(1):44-51. doi: 10.1093/eurpub/ckad181. Eur J Public Health. 2024. PMID: 37875008 Free PMC article.
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M, Gentili N, Balzi W, Musuraca G, Maltoni R, Masini C, Galardi F, Bertoni L, Massa I. Altini M, et al. Among authors: maltoni r. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):503-509. doi: 10.1080/14737167.2020.1764353. Epub 2020 May 13. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32403958
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer.
Danesi V, Massa I, Foca F, Delmonte A, Crinò L, Bronte G, Ragonesi M, Maltoni R, Manunta S, Cravero P, Andrikou K, Priano I, Balzi W, Gentili N, Burke T, Altini M. Danesi V, et al. Among authors: maltoni r. Cancers (Basel). 2022 Sep 15;14(18):4481. doi: 10.3390/cancers14184481. Cancers (Basel). 2022. PMID: 36139641 Free PMC article.
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Rocca A, Maltoni R, Passardi A, Massa I, Aquilina M, Ridolfi R, Ibrahim T, Cecconetto L, Sarti S, Pietri E, Nanni O, Amadori D. Rocca A, et al. Among authors: maltoni r. Cancer Chemother Pharmacol. 2010 Apr;65(5):871-6. doi: 10.1007/s00280-009-1092-8. Epub 2009 Aug 20. Cancer Chemother Pharmacol. 2010. PMID: 19693503 Clinical Trial.
82 results